(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3(Date:9/4/2008)...URNE, Australia, Sept. 4 /- Cytopia L...ncing enrolment for its Phase Ib/II,study of CYT99...cer agent,in patients with an aggressive form of ...)., The GBM clinical trial is the first Phase II ...ications for the company and the second in its,sui...
(Date:9/4/2008)...ata Published in ,The Lancet, and Presented at ESC... Results from a new international,study, the GISSI... dose of,omega-3 acid ethyl esters reduced all cau...cular reasons in patients with chronic heart,failu...line version of ,The,Lancet, and were presented at...
(Date:9/4/2008)...H, Switzerland, September 4 /- Axenti...al to assess the safety and tolerability,of a new ...e pulmonary,infection in cystic fibrosis patients....utic agent to be delivered directly to the site of...e the effects of two,different doses of the new dr...
(Date:9/4/2008)...nnouncements Remain on Schedule with Two Abstracts... Data Release in November 2008, BRIDGEWATER, N.J....,Inc., a specialty pharmaceutical company focused...disease, today announced the appointment of,Peter ...tors., Peter Garrambone,s career includes more th...
Breaking Medicine Technology:Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Social parasites of the smaller kind 150 1Social parasites of the smaller kind 150 2Sugary Sodas High in Diabetes Linked Compound 177 1Sugary Sodas High in Diabetes Linked Compound 177 2Sugary Sodas High in Diabetes Linked Compound 177 3DNA Sequencing Equipment Market to Fragment and Grow as Competition New Technologies Develop 178 1DNA Sequencing Equipment Market to Fragment and Grow as Competition New Technologies Develop 178 2Neuralstem Shares Accepted for Trading on Amex 28R 29 176 1Neuralstem Shares Accepted for Trading on Amex 28R 29 176 2...Preliminary results from,the immunotherapeutic can...r show a very good safety profile for SBG. Further...have been observed,among several patients that hav...noclonal antibody against neuroblastoma. , In line...ort for,the 1st quarter 2007, all 24 patients have...
...ored Clinical Trials , SOUTH SAN FRANCISCO, CA Jun...YTK) announced results from the analyses of,three ... as,monotherapy, one in patients with hepatocellul...in patients with hormone-refractory,prostate cance...f,kinesin spindle protein (KSP), a mitotic kinesin...
Other Medicine Technology:Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study 2Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study 3Cytokinetics Reports Additional Clinical Trials Data for Ispinesib 2Cytokinetics Reports Additional Clinical Trials Data for Ispinesib 3Cytokinetics Reports Additional Clinical Trials Data for Ispinesib 4Cytokinetics Reports Additional Clinical Trials Data for Ispinesib 5Cytokinetics Reports Additional Clinical Trials Data for Ispinesib 6Cytokinetics Reports Additional Clinical Trials Data for Ispinesib 7Cytokinetics Reports Additional Clinical Trials Data for Ispinesib 8...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: